Shire CEO: Mydayis To Be Big ADHD Drug, But No Ex-US Launch Planned (Yet)

 
• By Sten Stovall
  
ADHD
Shire CEO says resurrection of SHP465 part of plan to boost neuroscience revenues • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip